Publications (5)13.04 Total impact
-
Article: Arterial Hypertension and Resistance to Antihypertensive Treatment: a New Adverse Drug Reaction with Modafinil.
Thérapie 01/2013; 68(1):53-54. · 0.30 Impact Factor -
Article: Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug-drug interactions: a PharmacoVigilance study in France.
[show abstract] [hide abstract]
ABSTRACT: OBJECTIVE: Our aim was to characterize Adverse Drug Reactions (ADRs) related to drug-drug interactions (DDIs) related to involvement of cytochrome P450 (CYP450) isoenzymes in a pharmacovigilance database. METHODS: ADRs recorded by Midi-Pyrénées PharmacoVigilance center (France) between 1 January and 31 August 2008 were extracted from the French PharmacoVigilance Database (FPVD). RESULTS: Among the 1,205 reported ADRs, 16 (1.3 %), can be explained by involvement of CYP450 isoenzymes (including 4 "serious"). All interactions involved CYP inhibitors, mainly for CYP3A4/5. CONCLUSION: The percentage of ADRs reported in the pharmacovigilance database and related to CYP450-induced DDIs appears to be relatively low (~ 1-2 %).European Journal of Clinical Pharmacology 09/2012; · 2.85 Impact Factor -
Article: Potentially inappropriate medications in the elderly in France: a study in community pharmacies in 2011-2012.
European Journal of Clinical Pharmacology 08/2012; · 2.85 Impact Factor -
Article: Valvular heart disease in a patient taking 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy').
[show abstract] [hide abstract]
ABSTRACT: © 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.British Journal of Clinical Pharmacology 02/2012; 74(3):547-8. · 2.96 Impact Factor -
Article: Cancer Risk of Anti-TNF-α at Recommended Doses in Adult Rheumatoid Arthritis: A Meta-Analysis with Intention to Treat and per Protocol Analyses.
[show abstract] [hide abstract]
ABSTRACT: The risk of malignancies on TNF-α antagonists is controversial. The aim of this survey was to assess cancer risk on TNF-α antagonists in adult rheumatoid arthritis patients, including the five marketed drugs (infliximab, etanercept, adalimumab, golimumab and certolizumab) used in line with the New Drug Application. Furthermore, the relative interest of modified intention to treat or per protocol analyses to assess such sparse events remains unknown. Data sources were MEDLINE, CENTRAL, ISI Web of Science, ACR and EULAR meeting abstracts, scientific evaluation of the drugs leading to their marketing approval, and clinicaltrials.gov, until 31 December 2012.We selected double-blind randomized controlled trials in adult rheumatoid arthritis patients, including at least one treatment arm in line with New Drug Application. We performed random effect meta-analysis, with modified intention to treat and per protocol analyses. Thirty-three trials were included. There was no excess risk of malignancies on anti-TNF-α administered in line with New Drug Application in the per protocol model (OR, 0.93 95%CI[0.59-1.44]), as well as in the modified intention to treat model (OR, 1.27 95%CI[0.82-1.98]). There was a non-significant tendency for an excess non-melanoma skin cancer risk in both models (respectively, 1.37 [0.71-2.66] and 1.90 [0.98-3.67]). With fixed effect Peto model restricting to trials during at least 52 weeks, the overall cancer risk was respectively 1.60 [0.97-2.64] and 1.22 [0.72-2.08]. Whatever the model, modified intention to treat analysis led to higher estimations than per protocol analysis. The later may underestimate the treatment effect when assessing very sparse events and when many patients dropped out in placebo arms. In metaregression, there was no differential risk among the five drugs. This study did not find any evidence for an excess cancer risk on TNF-α antagonists in adult rheumatoid arthritis patients, but an excess cancer risk after several years of exposure cannot be ruled out. Both modified intention to treat and per protocol analyses should be presented in such safety analyses.PLoS ONE 01/2012; 7(11):e48991. · 4.09 Impact Factor
Top co-authors
Top Journals
Institutions
-
2012–2013
-
Centre Hospitalier Universitaire de Toulouse
Toulouse, Midi-Pyrenees, France -
Université de Toulouse
Toulouse, Midi-Pyrenees, France
-
